Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells $213,246.47 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,117 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $190.91, for a total value of $213,246.47. Following the completion of the transaction, the chief accounting officer directly owned 9,235 shares in the company, valued at $1,763,053.85. This represents a 10.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Patricia Carr also recently made the following trade(s):

• On Thursday, February 26th, Patricia Carr sold 1,253 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $194.11, for a total value of $243,219.83.
• On Friday, December 5th, Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $171.20, for a total value of $797,792.00.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $188.69 on Thursday. The company has a market cap of $11.62 billion, a price-to-earnings ratio of -31.61, a price-to-earnings-growth ratio of 0.37 and a beta of 0.22. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $198.00. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The firm has a 50 day moving average of $170.69 and a 200-day moving average of $153.18.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.49 by $0.15. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. Jazz Pharmaceuticals’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.51 EPS. On average, equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of JAZZ. Farther Finance Advisors LLC lifted its stake in Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 234 shares in the last quarter. Hilltop National Bank purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $36,000. Hantz Financial Services Inc. lifted its position in shares of Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 297 shares in the last quarter. LRI Investments LLC purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth about $38,000. Finally, Danske Bank A S bought a new stake in Jazz Pharmaceuticals in the 3rd quarter worth about $40,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Bank of America boosted their price objective on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Piper Sandler reiterated an “overweight” rating and issued a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Needham & Company LLC lifted their price target on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Finally, Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $214.57.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.